2024

Zanuso, V., Nash, T., Casolino, R., Armstrong, G., Pallise, O., Milne, J. and Braconi, C. (2024) Insights for clinical management from the real-life data of the centralized West of Scotland biliary cancer clinic. BMC Cancer, 24(1), 597. (doi: 10.1186/s12885-024-12279-6) (PMID:38755562) (PMCID:PMC11097428)

Agostini, A. et al. (2024) Identification of spatially-resolved markers of malignant transformation in Intraductal Papillary Mucinous Neoplasms. Nature Communications, 15(1), 2764. (doi: 10.1038/s41467-024-46994-2) (PMID:38553466) (PMCID:PMC10980816)

Casolino, R. et al. (2024) Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance. CA: A Cancer Journal for Clinicians, (doi: 10.3322/caac.21825) (PMID:38174605) (Early Online Publication)

2023

Golan, T., Casolino, R., Biankin, A. V. , Hammel, P., Whitaker, K. D., Hall, M. J. and Riegert-Johnson, D. L. (2023) Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake. Therapeutic Advances in Medical Oncology, (doi: 10.1177/17588359231189127) (PMID:37720496) (PMCID:PMC10504836) (Early Online Publication)

Paiella, S. et al. (2023) A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing. ESMO Open, 8(2), 100881. (doi: 10.1016/j.esmoop.2023.100881) (PMID:36822114) (PMCID:PMC10163165)

Casolino, R. et al. (2023) Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission. Lancet Oncology, 24(2), pp. 123-125. (doi: 10.1016/S1470-2045(23)00007-4) (PMID:36725142)

2022

Casolino, R., Corbo, V., Beer, P., Hwang, C.-I., Paiella, S., Silvestri, V., Ottini, L. and Biankin, A. V. (2022) Germline aberrations in pancreatic cancer: implications for clinical care. Cancers, 14(13), 3239. (doi: 10.3390/cancers14133239) (PMID:35805011) (PMCID:PMC9265115)

Casolino, R., Amato, F., Rae, C. , Puttagunta, S. and Braconi, C. (2022) Receptor tyrosine kinase co-amplification and benefit from HER2 inhibitors in biliary tract cancers. Journal of Hepatology, 76(5), pp. 1227-1229. (doi: 10.1016/j.jhep.2022.01.012) (PMID:35093472)

2021

Casolino, R. et al. (2021) Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. Journal of Clinical Oncology, 39(23), pp. 2617-2631. (doi: 10.1200/JCO.20.03238) (PMID:34197182) (PMCID:PMC8331063)

Casolino, R. et al. (2021) Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Annals of Oncology, 32(2), pp. 183-196. (doi: 10.1016/j.annonc.2020.11.013) (PMID:33248227) (PMCID:PMC7840891)

Froeling, F. E.M. , Casolino, R., Pea, A., Biankin, A. V. and Chang, D. K. (2021) Molecular subtyping and precision medicine for pancreatic cancer. Journal of Clinical Medicine, 10(1), 149. (doi: 10.3390/jcm10010149) (PMID:33406790) (PMCID:PMC7794969)

Articles

Zanuso, V., Nash, T., Casolino, R., Armstrong, G., Pallise, O., Milne, J. and Braconi, C. (2024) Insights for clinical management from the real-life data of the centralized West of Scotland biliary cancer clinic. BMC Cancer, 24(1), 597. (doi: 10.1186/s12885-024-12279-6) (PMID:38755562) (PMCID:PMC11097428)

Agostini, A. et al. (2024) Identification of spatially-resolved markers of malignant transformation in Intraductal Papillary Mucinous Neoplasms. Nature Communications, 15(1), 2764. (doi: 10.1038/s41467-024-46994-2) (PMID:38553466) (PMCID:PMC10980816)

Casolino, R. et al. (2024) Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance. CA: A Cancer Journal for Clinicians, (doi: 10.3322/caac.21825) (PMID:38174605) (Early Online Publication)

Golan, T., Casolino, R., Biankin, A. V. , Hammel, P., Whitaker, K. D., Hall, M. J. and Riegert-Johnson, D. L. (2023) Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake. Therapeutic Advances in Medical Oncology, (doi: 10.1177/17588359231189127) (PMID:37720496) (PMCID:PMC10504836) (Early Online Publication)

Paiella, S. et al. (2023) A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing. ESMO Open, 8(2), 100881. (doi: 10.1016/j.esmoop.2023.100881) (PMID:36822114) (PMCID:PMC10163165)

Casolino, R. et al. (2023) Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission. Lancet Oncology, 24(2), pp. 123-125. (doi: 10.1016/S1470-2045(23)00007-4) (PMID:36725142)

Casolino, R., Corbo, V., Beer, P., Hwang, C.-I., Paiella, S., Silvestri, V., Ottini, L. and Biankin, A. V. (2022) Germline aberrations in pancreatic cancer: implications for clinical care. Cancers, 14(13), 3239. (doi: 10.3390/cancers14133239) (PMID:35805011) (PMCID:PMC9265115)

Casolino, R., Amato, F., Rae, C. , Puttagunta, S. and Braconi, C. (2022) Receptor tyrosine kinase co-amplification and benefit from HER2 inhibitors in biliary tract cancers. Journal of Hepatology, 76(5), pp. 1227-1229. (doi: 10.1016/j.jhep.2022.01.012) (PMID:35093472)

Casolino, R. et al. (2021) Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. Journal of Clinical Oncology, 39(23), pp. 2617-2631. (doi: 10.1200/JCO.20.03238) (PMID:34197182) (PMCID:PMC8331063)

Casolino, R. et al. (2021) Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Annals of Oncology, 32(2), pp. 183-196. (doi: 10.1016/j.annonc.2020.11.013) (PMID:33248227) (PMCID:PMC7840891)

Froeling, F. E.M. , Casolino, R., Pea, A., Biankin, A. V. and Chang, D. K. (2021) Molecular subtyping and precision medicine for pancreatic cancer. Journal of Clinical Medicine, 10(1), 149. (doi: 10.3390/jcm10010149) (PMID:33406790) (PMCID:PMC7794969)